The systematic mixing guide pdf download

THE SYSTEMATIC MIXING GUIDE PDF DOWNLOAD TRIAL

Efficacy against confirmed symptomatic moderate to severe/critical and severe/critical COVID-19, by country for countries with greater than 100 moderate to severe/critical cases, centrally and in-country PCR-confirmed cases Genetic sequencing results for VOC, September-December, 2020 Efficacy against confirmed symptomatic severe/critical COVID-19 infection with onset в‰Ґ14 days and в‰Ґ28 days post-vaccination, per-protocol set Efficacy against confirmed symptomatic moderate to severe/critical COVID-19 infection with onset в‰Ґ14 days and в‰Ґ28 days post-vaccination, per-protocol set

THE SYSTEMATIC MIXING GUIDE PDF DOWNLOAD TRIAL

Appendix D: Clinical trial evidence summary for Janssen COVID-19 vaccine.Estimates of vaccine efficacy against asymptomatic infection, by dosing interval (SD/SD seronegative baseline efficacy set) Estimates of vaccine efficacy against the hospitalization, by dosing interval (SD/SD seronegative baseline efficacy set) Estimates of vaccine efficacy against the first occurrence of confirmed COVID-19 beginning after Dose 1 (SD/SD seronegative baseline efficacy set) Estimates of vaccine efficacy against the first occurrence of confirmed COVID-19 beginning в‰Ґ15 days after Dose 2, by dosing interval and age group (SD/SD seronegative baseline efficacy set) Estimates of vaccine efficacy against the first occurrence of confirmed COVID-19 beginning в‰Ґ15 days after Dose 2 in all participants, by dosing interval (SD/SD seronegative baseline efficacy set) Appendix C: Clinical trial evidence summary for AstraZeneca COVID-19 vaccine.Moderna vaccine efficacy against the first occurrence of symptomatic COVID-19 disease after dose 1 Appendix B: Clinical trial evidence summary for Moderna COVID-19 vaccine.Pfizer-BioNTech vaccine efficacy against the first occurrence of symptomatic COVID-19 disease after dose 1 and before dose 2 in adolescents 12 to 15 years of age Pfizer-BioNTech vaccine efficacy against the first occurrence of symptomatic COVID-19 disease after dose 1 and before dose 2 in participants 16 years of age and older Appendix A: Clinical trial evidence summary for Pfizer-BioNTech COVID-19 vaccine.Vaccination considerations for types of COVID-19 vaccines authorized for use in Canada Blood products, human immunoglobulin and timing of immunization.Ingredients of authorized, available COVID-19 vaccines that have been associated with allergic reactions in other products

Vaccine safety and adverse events following immunization (AEFI).

Simultaneous administration with other vaccines.

Immunization schedule, by COVID-19 vaccine COVID-19 vaccines available for use in Canada

Preparations of COVID-19 vaccines authorized and available for use in Canada.

Summary of risk factors for severe outcomes from COVID-19 and increased riskВ of exposure to COVID-19 Organization: Public Health Agency of Canada

The systematic mixing guide pdf download